Results 21 to 30 of about 109,463 (148)

Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C

open access: yesAnales de Pediatría, 2019
Resumen: Introducción: El objetivo del estudio fue evaluar la seguridad y la eficacia de la combinación de ledipasvir/sofosbuvir en la infección crónica por el genotipo 1 y 4 del virus de la hepatitis C (VHC) en pacientes pediátricos.
Jesús Quintero   +7 more
doaj   +1 more source

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

open access: yes, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo   +10 more
core   +1 more source

Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia

open access: yesRevista Colombiana de Gastroenterología, 2014
Introducción: el virus de la hepatitis C afecta a cerca de 170 millones de personas en el mundo. La organización mundial de la salud (OMS) estima una prevalencia mundial del 2%.
Jhon Edison Prieto Ortíz   +3 more
doaj   +1 more source

Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents

open access: yesAnales de Pediatría (English Edition), 2019
Introduction: The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients.
Jesús Quintero   +7 more
doaj   +1 more source

HCV epidemiology in high-risk groups and the risk of reinfection [PDF]

open access: yes, 2016
Injecting risk behaviours among people who inject drugs (PWID) and high-risk sexual practices among men who have sex with men (MSM) are important routes of hepatitis C virus (HCV) transmission.
Dalgard, Olav   +6 more
core   +2 more sources

Exploring associations between perceived HCV status and injecting risk behaviors among recent initiates to injecting drug use in Glasgow [PDF]

open access: yes, 2008
The aim of this study was to explore the influence of testing for hepatitis C virus (HCV) and perceived HCV status on injecting risk behavior. A cross-sectional, community-wide survey was undertaken at multiple sites throughout Greater Glasgow during ...
Anderson, Niall   +5 more
core   +1 more source

Sialoadenitis crónica revelando una hepatitis: a propósito de un caso [PDF]

open access: yes, 2004
Un varón de 53 años fue remitido con una historia clínica de neuropatía sensitiva periférica y de enfermedad de Raynaud, por sospechar un síndrome de Sjögren (SS).
Courtois, Bruno   +2 more
core   +1 more source

Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative Disease [PDF]

open access: yes, 1992
Epstein-Barr virus (EBV)—associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression.
Anthony J. Demetris   +26 more
core   +1 more source

Low prevalence of hepatitis C co-infection in recently HIV-infected minority men who have sex with men in Los Angeles: a cross-sectional study. [PDF]

open access: yes, 2015
BackgroundGeographic and sociodemographic characterization of hepatitis C virus (HCV) transmission amongst men who have sex with men (MSM) has been limited.
Bhattacharya, Debika   +7 more
core   +2 more sources

CD4+T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C viruscoinfected patients [PDF]

open access: yes, 2017
To characterize peripheral blood natural killer (NK) cells phenotypes by flow cytometry as potential biomarker of liver fibrosis in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients.
Cahn, Pedro   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy